No abstract

Aims To determine what predicts health visitors’ family‐focused practice with mothers who have mental illness. To explore health visitors’ experiences of family‐focused practice and what factors, if any, enable and/or hinder it. Design A sequential mixed‐methods design was employed. Methods In Phase 1, a total of 230 health visitors, in five Health and Social Care Trusts in the UK were recruited using convenience sampling and completed the Family Focused Mental Health Practice Questionnaire. Three multiple regression models were developed to test whether workload (Model I), professional knowledge (Model II) and health visitors’ professional and personal experience (Model III) predicted their family‐focused practice. In Phase 2, 10 health visitors, who completed the questionnaire, participated in semi‐structured interviews to describe their experiences of family‐focused practice. The data collection of the two phases was conducted from September 2017 ‐ September 2018. Results Model III was significant. While personal experience of parenting was positively associated with family‐focused practice, length registered as a health visitor and personal experience of mental illness was negatively associated. Qualitative findings suggested that increasing years of professional experience and personal experience of mental illness enabled health visitors to support mothers and their children, but not other adult family members, including partners. Limited skills and knowledge to support mothers with severe mental illness (i.e. schizophrenia) hindered family‐focused practice. Conclusion This study advances understanding of how health visitors’ professional and personal experiences can influence their family‐focused practice and highlights the importance of organizations promoting their capacity to support mothers with severe mental illness and to include mothers’ partners. Impact A clear understanding of factors affecting health visitors’ capacity to engage in family‐focused practice will help to inform policy, education and practice in health visiting; with potential to improve outcomes for the whole family.

Maternal mental illness is a major public health issue and can adversely affect the whole family. Increasingly, research and policy are recognizing the benefits of a family-focused approach to practice, an approach that emphasizes the family as the unit of care. This review was conducted with the aim of systematically analyzing the qualitative literature surrounding health visitors' family-focused practice with mothers who have mental illness and/or substance misuse. Through the synthesis, we developed three main findings: (a) parents' needs regarding health visitors' family-focused practice, (b) the ambiguity of mental illness in health visiting, and (c) the challenges of family-focused practice in health visiting. Above all, health visitors, families, and mothers with mental illness experience many challenges in familyfocused practice, even though it is both desirable and beneficial. This calls for a deeper understanding of how family-focused practice can be effectively practiced in health visiting.

BackgroundWorldwide maternal mental illness poses a major public health issue. Supporting maternal mental health and family health is a core aspect of home visiting. Increasingly the benefits of family focused treatments to maternal mental illness are being recognised. However, there are few reliable and valid measures that attempt to assess this type of practice.ObjectivesTo explore the psychometric properties of the Family Focused Mental Health Practice Questionnaire in a population of home visitors.MethodsHome visitors (n = 230) from across a single region of the United Kingdom completed the Family Focused Mental Health Practice Questionnaire. Participants were all females, had a mean age of 44 years, and had an average of 11 years’ experience of home visiting. Exploratory factor analysis was used to explore the factor structure of the questionnaire in this population while Cronbach’s alpha was used to assess the internal consistency of questionnaire subscales.ResultsExploratory factor analysis revealed a 3-factor solution where each factor contained at least three questionnaire items and had eigenvalues ≥ 1.0. Checks for internal consistency revealed that one factor was unsatisfactory (α < 0.6), which was subsequently discarded. A further exploratory factor analysis supported a 2 factor solution. The factors were named: professional influences on family focused practice and organisational influences on family focused practice. Cronbach’s alpha for the new scale was 0.949.ConclusionAs home visitors play a key role in supporting parents who have mental illness and their families, it is important to assess their practice using a reliable measure. Our psychometric evaluation has created a more valid, reliable and concise measure that can be used to examine home visitors’ family focused practice.

Apicomplexans are widespread parasites of humans and other animals, and include the causative agents of malaria (Plasmodium species) and toxoplasmosis (Toxoplasma gondii). Existing anti-apicomplexan therapies are beset with issues around drug resistance and toxicity, and new treatment options are needed. The mitochondrial electron transport chain (ETC) is one of the few processes that has been validated as a drug target in apicomplexans. To identify new inhibitors of the apicomplexan ETC, we developed a Seahorse XFe96 flux analyzer approach to screen the 400 compounds contained within the Medicines for Malaria Venture ‘Pathogen Box’ for ETC inhibition. We identified six chemically diverse, on-target inhibitors of the ETC in T. gondii, at least four of which also target the ETC of Plasmodium falciparum. Two of the identified compounds (MMV024937 and MMV688853) represent novel ETC inhibitor chemotypes. MMV688853 belongs to a compound class, the aminopyrazole carboxamides, that were shown previously to target a kinase with a key role in parasite invasion of host cells. Our data therefore reveal that MMV688853 has dual targets in apicomplexans. We further developed our approach to pinpoint the molecular targets of these inhibitors, demonstrating that all target Complex III of the ETC, with MMV688853 targeting the ubiquinone reduction (Qi) site of the complex. Most of the compounds we identified remain effective inhibitors of parasites that are resistant to Complex III inhibitors that are in clinical use or development, indicating that they could be used in treating drug resistant parasites. In sum, we have developed a versatile, scalable approach to screen for compounds that target the ETC in apicomplexan parasites, and used this to identify and characterize novel inhibitors.